Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abingworth Closes New Fund

This article was originally published in Start Up

Executive Summary

Abingworth's new fund puts the London-based venture firm in position to continue investing heavily on both sides of the Atlantic.

You may also be interested in...



Diversification vs. Sector Focus: Longitude, Enterprise Seek Latitude in Life Sciences

The age of specialization is not over for venture capital firms. The health care team from Pequot Ventures left the hedge-fund heavy firm to start Longitude Capital. Meanwhile, Enterprise Partners Venture Capital is said to be raising a health care only fund.

Diversification vs. Sector Focus: Longitude, Enterprise Seek Latitude in Life Sciences

The age of specialization is not over for venture capital firms. The health care team from Pequot Ventures left the hedge-fund heavy firm to start Longitude Capital. Meanwhile, Enterprise Partners Venture Capital is said to be raising a health care only fund.

Illumina Buys Solexa

The $600 million Illumina is paying to acquire next-generation sequencing company Solexa says more about current market drivers and meeting Illumina's immediate need for growth than it does about the technology's future application as a means of achieving the oft-touted goal of the $1,000 genome sequence.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel